Physician profile
Lin Soe
NPI 1467524900
$14,187.77
in general payments reported to CMS, 2019-2025
79 companies · $3,772 in 2025
The $3,772 reported for 2025 was more than what 78% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,141 · 2020: $391 · 2021: $155 · 2022: $2,185 · 2023: $2,790 · 2024: $3,754 · 2025: $3,772.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $41.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,274.54 |
| Education | $41.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $965.64 | 2019-2025 | Opdivo, Opdualag |
| Janssen Biotech, INC. | $946.65 | 2019-2025 | Tecvayli, Rybrevant, Darzalex |
| Astrazeneca Pharmaceuticals LP | $770.58 | 2019-2025 | Enhertu, Tagrisso, Lynparza |
| Novartis Pharmaceuticals Corporation | $696.73 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $687.59 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Pfizer INC. | $685.20 | 2019-2025 | |
| Daiichi Sankyo INC. | $624.09 | 2019-2025 | Enhertu, Vanflyta, Injectafer |
| Genentech USA, INC. | $614.96 | 2019-2025 | Columvi, Lunsumio, Venclexta |
| Celgene Corporation | $464.32 | 2022-2025 | Reblozyl, Opdualag, Pomalyst |
| Exelixis INC. | $462.17 | 2019-2025 | Cabometyx |
| Glaxosmithkline, LLC. | $417.54 | 2022-2025 | Ojjaara, Zejula, Jemperli |
| Astellas Pharma US INC | $408.52 | 2019-2025 | Xospata, Vyloy, Xtandi |
| Seagen INC. | $398.82 | 2019-2023 | Adcetris, Tivdak, Padcev |
| Amgen INC. | $376.08 | 2019-2023 | Lumakras, Blincyto, Nplate |
| Eisai INC. | $368.64 | 2022-2025 |
Show all 79 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $339.99 | 2019-2025 | Iclusig, Fruzaqla, Alunbrig |
| Lilly USA, LLC | $300.55 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Blueprint Medicines Corporation | $287.92 | 2020-2025 | Ayvakit |
| Adc Therapeutics America, INC. | $266.31 | 2023-2025 | |
| Abbvie INC. | $254.51 | 2023-2025 | Venclexta |
| Pharmaessentia USA Corporation | $208.21 | 2023-2024 | Besremi |
| Sobi, INC | $175.68 | 2022-2025 | |
| Array Biopharma INC | $159.75 | 2023-2025 | Braftovi, Lorbrena, Mektovi |
| Rigel Pharmaceuticals, INC. | $157.84 | 2022-2025 | Rezlidhia, Tavalisse, Gavreto |
| Puma Biotechnology, INC. | $153.47 | 2019-2025 | Nerlynx |
| Pharmacyclics LLC, An Abbvie Company | $151.35 | 2021-2023 | Imbruvica, Epkinly |
| Jazz Pharmaceuticals INC. | $144.30 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $135.52 | 2022-2025 | |
| Genzyme Corporation | $112.97 | 2019-2024 | |
| Incyte Corporation | $111.04 | 2019-2025 | Monjuvi |
| Karyopharm Therapeutics INC. | $108.55 | 2023-2025 | Xpovio |
| Regeneron Healthcare Solutions, INC. | $105.36 | 2022-2025 | Libtayo |
| Emd Serono, INC. | $98.59 | 2022-2025 | |
| Taiho Oncology, INC. | $97.93 | 2023-2025 | |
| Syndax Pharmaceuticals, INC. | $94.80 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $93.22 | 2022-2024 | Onivyde, Tazverik, Somatuline Depot |
| Stemline Therapeutics INC. | $92.54 | 2023-2025 | Orserdu, Elzonris |
| Gilead Sciences, INC. | $87.82 | 2023-2024 | Trodelvy |
| Alexion Pharmaceuticals, INC. | $86.61 | 2019-2025 | Ultomiris |
| Agios Pharmaceuticals, INC. | $85.08 | 2024-2025 | Pyrukynd |
| Janssen Scientific Affairs, LLC | $83.34 | 2023 | Tecvayli |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.12 | 2022-2025 | Gilotrif |
| Apellis Pharmaceuticals, INC. | $75.85 | 2022-2024 | Empaveli |
| Mirati Therapeutics, INC. | $67.23 | 2023-2024 | Krazati |
| Aveo Pharmaceuticals, INC. | $63.87 | 2022-2025 | Fotivda |
| Alnylam Pharmaceuticals INC. | $59.42 | 2024-2025 | Givlaari, Onpattro |
| Servier Pharmaceuticals LLC | $55.48 | 2024-2025 | |
| Genmab U.S., INC. | $54.64 | 2024-2025 | Epkinly |
| Menarini Silicon Biosystems, INC. | $46.63 | 2025 | |
| Pharmacosmos Therapeutics INC. | $45.41 | 2024-2025 | Monoferric |
| Beone Medicines USA, INC. | $44.32 | 2025 | Tevimbra, Brukinsa |
| Accord Healthcare, INC. | $43.51 | 2025 | |
| Secura Bio, INC. | $41.88 | 2021 | |
| Springworks Therapeutics, INC. | $38.82 | 2024-2025 | Ogsiveo |
| Tersera Therapeutics LLC | $38.37 | 2025 | Zoladex |
| Tempus Ai, INC | $38.32 | 2025 | Xt Cdx |
| Coherus Oncology, INC. | $38.17 | 2025 | Loqtorzi |
| Geron Corporation | $37.09 | 2025 | Rytelo |
| Clovis Oncology, INC. | $36.65 | 2020-2022 | |
| Recordati_rare_diseases_inc. | $35.56 | 2023-2025 | Sylvant, Enjaymo |
| Immunogen, INC. | $32.26 | 2023 | Elahere |
| Medtronic, INC. | $29.30 | 2024 | Synchromedii |
| Acrotech Biopharma INC. | $25.90 | 2021 | |
| Tesaro, INC. | $24.55 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $23.62 | 2019 | |
| Kite Pharma, INC. | $19.80 | 2025 | Yescarta |
| Deciphera Pharmaceuticals INC. | $19.56 | 2022 | |
| Amag Pharmaceuticals, INC. | $18.90 | 2022 | |
| Sirtex Medical INC | $18.79 | 2023 | Sir-Spheres Microspheres |
| Cti Biopharma Corp. | $18.59 | 2022 | |
| Beigene USA, INC. | $16.47 | 2025 | Tevimbra |
| Morphosys, US INC. | $16.35 | 2023 | Monjuvi |
| Fennec Pharmaceuticals, INC. | $15.66 | 2025 | Fyarro |
| Cumberland Pharmaceuticals, INC. | $15.58 | 2023 | Sancuso |
| G1 Therapeutics, INC. | $15.11 | 2023 | Cosela |
| Janssen Pharmaceuticals, INC | $14.30 | 2022 | |
| Organon LLC | $13.78 | 2023 | Ontruzant |
| Roche Diagnostics Corporation | $13.63 | 2020 | |
| Epizyme, INC. | $11.50 | 2021 |
Drugs and devices associated with these payments
Enhertu $592Keytruda $409Cabometyx $397Tecvayli $387Opdivo $339Lenvima $270Jaypirca $261Imbruvica $254Venclexta $252Pluvicto $244Lynparza $239Rybrevant $227Darzalex $227Ojjaara $211Besremi $208Lorbrena $202Epkinly $198Lunsumio $177Columvi $177Padcev $172Carvykti $171Zynlonta $168Adcetris $162Braftovi $160Zejula $153Reblozyl $144Mektovi $141Inlyta $139Iclusig $135Jemperli $122Tagrisso $120Xalkori $114Xtandi $114Doptelet $111Tavalisse $110Rezlidhia $110Vanflyta $110Xpovio $109Erleada $108Fruzaqla $105Xospata $102Vyloy $101Polivy $101Lonsurf $97.93Inqovi $97.93Scemblix $97.18Elrexfio $95.58Tivdak $93.75Nerlynx $90.54Ibrance $90.40Nubeqa $85.85Xofigo $85.85Libtayo $85.72Pyrukynd $85.08Opdualag $83.07Gavreto $70.39Orserdu $67.50Krazati $67.23Zepzelca $61.79Empaveli $61.39Talvey $60.86Tecentriq $57.57Mekinist $55.23Pomalyst $55.16Monjuvi $54.71Lutathera $53.93Onivyde $52.75Verzenio $52.56Bavencio $52.32Fotivda $51.57Phesgo $49.52Injectafer $48.17Cellsearch $46.63Monoferric $45.41Ayvakit $44.39Bosulif $44.33Tevimbra $43.81Camcevi $43.51Givlaari $43.51Enjaymo $43.23Tukysa $43.03Ultomiris $42.79Blenrep $42.22Vonjo $40.38Alunbrig $39.07Zoladex $38.37Xt Cdx $38.32Loqtorzi $38.17Retevmo $38.05Rytelo $37.09Tazverik $36.32Imfinzi $35.28Voranigo $33.01Talzenna $32.66Elahere $32.26Gilotrif $30.08Ziihera $29.73Synchromedii $29.30Keytruda Qlex $28.76Paxlovid $28.61
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lin Soe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.